Multihance

Multihance - General Information

In magnetic resonance imaging (MRI), visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in the T2. When placed in a magnetic field, Multihance shortens both the T1 and the T2 relaxation times in tissues where it accumulates. At clinical doses, Multihance primarily affects the T1 relaxation time, thus producing an increase in signal intensity. Multihance does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars).

Pharmacology of Multihance

Gadobenate dimeglumine shares the pharmacokinetic properties of the ECF contrast agent gadopentetate dimeglumine; however, gadobenate differs in that is also selectively taken-up by hepatocytes and excreted via the bile (up to 5% of dose). The elimination half-life of gadobenate dimeglumine is approximately 1 hour. It is not metabolized.

Additional information about Multihance

Multihance Indication: For magnetic resonance imaging (MRI) of the central nervous system in adults to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine, and associated tissues.
Mechanism Of Action: Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. Paramagnetic agents have unpaired electrons that generate a magnetic field about 700 times larger than the proton's field, thus disturbing the proton's local magnetic field. When the local magnetic field around a proton is disturbed, its relaxation process is altered. MR images are based on proton density and proton relaxation dynamics. MR instruments can record 2 different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and the T2 (spin-spin or transverse relaxation time). In magnetic resonance imaging (MRI), visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in the T2. When placed in a magnetic field, Multihance shortens both the T1 and the T2 relaxation times in tissues where it accumulates. At clinical doses, Multihance primarily affects the T1 relaxation time, thus producing an increase in signal intensity. Multihance does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars).
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Gadobenate Dimeglumine
Synonyms: Gadobenic acid
Drug Category: Contrast Media
Drug Type: Small Molecule; Approved

Other Brand Names containing Gadobenate Dimeglumine: Gd-BOPTA; Gd-BOPTA/Dimeg; Multihance; Multihance Multipack;
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Plasma protein binding is low, weak, and transient.
Biotransformation: Not metabolized
Half Life: 1 hour
Dosage Forms of Multihance: Solution Intravenous
Chemical IUPAC Name: 2-[carboxymethyl-[2-[2-[carboxymethyl-(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]ethyl]amino]-3-phenylmethoxypropanoate; gadolinium(+3) cation; (2R,3R,4R,5S)-6-methylaminohexane-1,2,3,4,5-pentol
Chemical Formula: C36H62GdN5O21
Gadobenate Dimeglumine on Wikipedia: Not Available
Organisms Affected: Humans and other mammals